Introduction/Background Breast cancer (BC) is becoming increasingly prevalent in women greater than 65 years of age. Our objective was to analyze the epidemiological, clinical, therapeutic, and prognostic of (BC) in older women.

Methodology A retrospective study of 45 patients above the age of 65 years diagnosed with breast cancer from January 2014 to December 2019 and treated in Mohamed Taher Maamouri Hospital of Nabeul, Tunisia.

Results Among 356 women who had (BC) during the study period, 54 (15.16%) were aged 65 and over. The average age in our series was 71 years. Stage T2 was predominantly observed (46.3%), and forms classified T4 represented (20.4%) of the tumors. The disease was metastatic at diagnosis in one case. The lymph node was positive in 19 patients (35.8%). 66.7% of the patients were luminal A, 14.9% were triple-negative 16.7% were luminal B, and 1.9% were human epidermal growth factor receptor-2-positive type.

Neoadjuvant chemotherapy was performed in 8 cases of locally advanced cancers. Surgical treatment was radical and conservative in respectively 37% and 61.1% of cases. Adjuvant Chemo and radiotherapies were performed in respectively 29.6% and 79.6% of cases. Hormonotherapy was administered to 83.3%of patients. Trastuzumab was administered to 3.7% of the patients.

Recurrences were noted in 1.9% of cases, and distant metastases in 5.5% of cases.

Overall survival and progression-free survival at 5 years were 85.3% and 90.6% respectively.

Conclusion Breast cancer in the elderly has, however, poorer outcomes with lower survival rates compared to younger subjects.

Disclosures The conclusions on breast cancer in older women are similar to those on other forms of cancer in the elderly. The main determinants of outcome and survival are tumor characteristics and comorbidities, not age itself.